QQQ   445.12 (+0.07%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
QQQ   445.12 (+0.07%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
QQQ   445.12 (+0.07%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
QQQ   445.12 (+0.07%)
AAPL   171.26 (-1.18%)
MSFT   421.06 (-0.09%)
META   489.86 (-0.81%)
GOOGL   150.75 (-0.08%)
AMZN   181.21 (+0.77%)
TSLA   176.88 (-1.64%)
NVDA   906.99 (+0.50%)
NIO   4.69 (+0.43%)
AMD   180.63 (+0.58%)
BABA   72.25 (+0.92%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   117.63 (-1.27%)
CGC   9.33 (-2.30%)
GE   177.24 (-1.60%)
DIS   123.49 (+2.07%)
AMC   3.81 (-12.21%)
PFE   27.78 (+0.00%)
PYPL   66.53 (-0.06%)
XOM   115.23 (+0.23%)
NASDAQ:PEAR

Pear Therapeutics (PEAR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
7.75 million shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PEAR stock logo

About Pear Therapeutics Stock (NASDAQ:PEAR)

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

PEAR Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Pear Therapeutics Inc Class A PEARQ
PEARQ Pear Therapeutics, Inc.
Pear Therapeutics, Inc. (PEARQ)
See More Headlines
Receive PEAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:PEAR
Fax
N/A
Employees
300
Year Founded
N/A

Profitability

Net Income
$-75,490,000.00
Net Margins
-594.70%
Pretax Margin
-594.70%

Debt

Sales & Book Value

Annual Sales
$12.69 million
Book Value
$0.22 per share

Miscellaneous

Free Float
98,918,000
Market Cap
$4.17 million
Optionable
Not Optionable
Beta
0.45
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Corey M. McCann M.D. (Age 43)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $702.45k
  • Mr. Christopher D. T. Guiffre J.D. (Age 55)
    M.B.A., MBA, CFO, COO, Treasurer & Assistant Sec.
    Comp: $564.37k
  • Ms. Julia M. Strandberg M.B.A. (Age 48)
    Chief Commercial Officer
    Comp: $582.43k
  • Mr. Ronan P. O'Brien J.D. (Age 50)
    Chief Compliance Officer, Gen. Counsel & Sec.
  • Ms. Meara Murphy
    Sr. Director of Corp. Communications
  • Dr. Yuri Maricich M.B.A. (Age 43)
    M.D., Chief Medical Officer & Head of Devel.
  • Mr. Chris Valosky M.B.A.
    VP of Sales
  • Ms. Katherine Jeffery M.Sc. (Age 56)
    Chief People Officer
  • Ms. Erin K. Brenner (Age 50)
    Chief Product Devel. Officer
  • Ms. Ellen E. Snow CPA (Age 50)
    CGMA, VP & Corp. Controller

PEAR Stock Analysis - Frequently Asked Questions

How do I buy shares of Pear Therapeutics?

Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PEAR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners